{"id":"hydracarbazine","rwe":[{"pmid":"5994381","year":"1966","title":"[Value of the combination of a heterocyclic tertiary amine (pempidine) and a substituted hydralazine (hydracarbazine) in the ambulatory treatment of arterial hypertension].","finding":"","journal":"Semaine therapeutique","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"hydracarbazin","offLabel":[],"synonyms":["hydracarbazine","TH-2151","hydracarbazin","hydracarbizine"],"timeline":[],"approvals":[],"brandName":"Hydracarbazin","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like a city, and hydracarbazin is a key that unlocks a specific door to allow the right things to happen. By binding to proteins or receptors, hydracarbazin helps to regulate the city's functions, such as communication between cells or the movement of molecules. This can help to treat various diseases, but the exact details depend on the specific target and mechanism of action.","oneSentence":"Hydracarbazin works by binding to specific proteins or receptors in the body to produce a therapeutic effect.","technicalDetail":"Hydracarbazin's mechanism of action is likely to involve the modulation of protein-protein interactions or the binding to specific receptors, which can influence downstream signaling pathways and cellular responses."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5125","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYDRACARBAZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:54:24.920468","biosimilars":[],"competitors":[],"genericName":"hydracarbazine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"6CTK2FB9QM","CHEBI":"CHEBI:136055","INN_ID":"1594","UMLSCUI":"C2697633","ChEMBL_ID":"CHEMBL2106246","DRUGBANK_ID":"DB09243","PUBCHEM_CID":"71653"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1966 Oct","pmid":"5994381","title":"[Value of the combination of a heterocyclic tertiary amine (pempidine) and a substituted hydralazine (hydracarbazine) in the ambulatory treatment of arterial hypertension].","journal":"Semaine therapeutique"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydracarbazin, also known as HYDRACARBAZINE, is a small molecule drug with unknown target and drug class. Its commercial status is currently unknown, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its mechanism of action and safety considerations. Further research is needed to fully understand this compound.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}